In addition, exploiting the mechanism by which NLRP6 suppresses gastric tumorigenesis via P14ARF–Mdm2–P53-dependent cellular senescence may also prove to be a promising strategy for gastric cancer therapy. This evidence concerns the gene MDM2 and gastric cancer.